Summary
4.59
-0.20
(-4.18%)
04/10/2026
Foghorn Therapeutics Inc. (FHTX)
Key Facts
| 1 Day | 1 Week | 1 Month | 3 Months | 6 Months | 1 Year | 5 Years |
| -4.18 | -5.94 | -16.39 | -28.06 | 13.05 | 42.11 | -62.19 |
Last 730 data points are shown. To view all data, Upgrade to PRO plan!
Fundamental Ratings
| Category | Rating |
| Main Rating | C |
| Recommended Rating | Sell |
| DCF | Strong Sell |
| ROE | Strong Buy |
| ROA | Strong Sell |
| Debt/Equity | Strong Sell |
| P/E | Strong Sell |
| P/B | Strong Sell |
Earnings
| Trading Data | ||
| Close | 4.59 | |
| Open | 4.78 | |
| High | 4.78 | |
| Low | 4.53 | |
| Volume | 160,900 | |
| Change | -0.20 | |
| Change % | -4.18 | |
| Avg Volume (20 Days) | 173,776 | |
| Volume/Avg Volume (20 Days) Ratio | 0.93 | |
| 52 Week Range | 3.14 - 6.95 | |
| Price vs 52 Week High | -33.96% | |
| Price vs 52 Week Low | 46.18% | |
| Range | -3.97 | |
| Gap Up/Down | -0.09 | |
Profitibility | ||
| Market Capitalization (Mln) | 256 | |
| Revenue per share | 0.4908 | |
| Net Income per share | -1.1795 | |
| Dividend Yield | 0.0000 | |
| Dividend Share | 0.00% | |
Valuations | ||
| Enterprise Value | 0.00% | |
| PE Ratio | -3.8916 | |
| PB Ratio | 0.0000 | |
| PTB Ratio | 0.0000 | |
Liquidity | ||
| Debt/Equity Ratio | 0.0000 | |
| Net Debt/EBIDTA Ratio | 0.0000 | |
| Current Ratio | 0.0000 | |
Enterprise Value and Cash Flow | ||
| EV/Sales Ratio | 0.0000 | |
| EV/EBIDTA Ratio | 0.0000 | |
| EV/Free Cash Flow Ratio | 0.0000 | |
04/09 07:00 EST - globenewswire.com
Foghorn Therapeutics to Present New Preclinical Data for Selective SMARCA2 Inhibitor FHD-909 and Selective CBP, EP300 and ARID1B Degrader Programs at the 2026 AACR Annual Meeting
New preclinical data for FHD-909 (LY4050784) reinforcing the potential for expansion opportunities in combination with an anti-PD-1 antibody in SMARCA4 (BRG1)-mutant lung cancer
Foghorn Therapeutics to Present New Preclinical Data for Selective SMARCA2 Inhibitor FHD-909 and Selective CBP, EP300 and ARID1B Degrader Programs at the 2026 AACR Annual Meeting
New preclinical data for FHD-909 (LY4050784) reinforcing the potential for expansion opportunities in combination with an anti-PD-1 antibody in SMARCA4 (BRG1)-mutant lung cancer
03/29 02:29 EST - defenseworld.net
Contrasting Foghorn Therapeutics (NASDAQ:FHTX) and Rocket Pharmaceuticals (NASDAQ:RCKT)
Foghorn Therapeutics (NASDAQ: FHTX - Get Free Report) and Rocket Pharmaceuticals (NASDAQ: RCKT - Get Free Report) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their profitability, valuation, analyst...
Contrasting Foghorn Therapeutics (NASDAQ:FHTX) and Rocket Pharmaceuticals (NASDAQ:RCKT)
Foghorn Therapeutics (NASDAQ: FHTX - Get Free Report) and Rocket Pharmaceuticals (NASDAQ: RCKT - Get Free Report) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their profitability, valuation, analyst...
03/11 18:55 EST - zacks.com
Foghorn Therapeutics Inc. (FHTX) Reports Q4 Loss, Beats Revenue Estimates
Foghorn Therapeutics Inc. (FHTX) came out with a quarterly loss of $0.34 per share versus the Zacks Consensus Estimate of a loss of $0.28. This compares to a loss of $0.3 per share a year ago.
Foghorn Therapeutics Inc. (FHTX) Reports Q4 Loss, Beats Revenue Estimates
Foghorn Therapeutics Inc. (FHTX) came out with a quarterly loss of $0.34 per share versus the Zacks Consensus Estimate of a loss of $0.28. This compares to a loss of $0.3 per share a year ago.
03/11 16:09 EST - globenewswire.com
Foghorn Therapeutics Provides Financial Update for 2025 and 2026 Strategic Outlook
FHD-909 (LY4050784) Phase 1 dose-escalation advancing as planned, targeting SMARCA4 (BRG1)-mutant cancers with a focus on non-small cell lung cancer (NSCLC)
Foghorn Therapeutics Provides Financial Update for 2025 and 2026 Strategic Outlook
FHD-909 (LY4050784) Phase 1 dose-escalation advancing as planned, targeting SMARCA4 (BRG1)-mutant cancers with a focus on non-small cell lung cancer (NSCLC)
03/11 04:26 EST - defenseworld.net
Foghorn Therapeutics Inc. (NASDAQ:FHTX) Receives Consensus Recommendation of “Moderate Buy” from Brokerages
Shares of Foghorn Therapeutics Inc. (NASDAQ: FHTX - Get Free Report) have been assigned a consensus rating of "Moderate Buy" from the ten ratings firms that are covering the company, MarketBeat.com reports. One investment analyst has rated the stock with a sell rating, eight have given a buy rating...
Foghorn Therapeutics Inc. (NASDAQ:FHTX) Receives Consensus Recommendation of “Moderate Buy” from Brokerages
Shares of Foghorn Therapeutics Inc. (NASDAQ: FHTX - Get Free Report) have been assigned a consensus rating of "Moderate Buy" from the ten ratings firms that are covering the company, MarketBeat.com reports. One investment analyst has rated the stock with a sell rating, eight have given a buy rating...
02/24 07:00 EST - globenewswire.com
Foghorn Therapeutics to Participate in Two Upcoming Investor Conferences
WATERTOWN, Mass., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Foghorn® Therapeutics Inc. (Nasdaq: FHTX), a clinical-stage biotechnology company pioneering a new class of medicines that treat serious diseases by correcting abnormal gene expression, today announced that management will participate in the TD...
Foghorn Therapeutics to Participate in Two Upcoming Investor Conferences
WATERTOWN, Mass., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Foghorn® Therapeutics Inc. (Nasdaq: FHTX), a clinical-stage biotechnology company pioneering a new class of medicines that treat serious diseases by correcting abnormal gene expression, today announced that management will participate in the TD...
02/23 07:00 EST - globenewswire.com
Foghorn Therapeutics Strengthens Financial Leadership with Appointment of Ryan Maynard as Chief Financial Officer
WATERTOWN, Mass., Feb. 23, 2026 (GLOBE NEWSWIRE) -- Foghorn® Therapeutics Inc. (Nasdaq: FHTX), a clinical-stage biotechnology company pioneering a new class of medicines that treat serious diseases by correcting abnormal gene expression, today announced that Ryan Maynard will join the company as...
Foghorn Therapeutics Strengthens Financial Leadership with Appointment of Ryan Maynard as Chief Financial Officer
WATERTOWN, Mass., Feb. 23, 2026 (GLOBE NEWSWIRE) -- Foghorn® Therapeutics Inc. (Nasdaq: FHTX), a clinical-stage biotechnology company pioneering a new class of medicines that treat serious diseases by correcting abnormal gene expression, today announced that Ryan Maynard will join the company as...
02/14 03:24 EST - defenseworld.net
Foghorn Therapeutics Inc. (NASDAQ:FHTX) Receives Average Rating of “Buy” from Brokerages
Shares of Foghorn Therapeutics Inc. (NASDAQ: FHTX - Get Free Report) have received a consensus rating of "Buy" from the nine analysts that are presently covering the company, MarketBeat Ratings reports. One investment analyst has rated the stock with a sell recommendation, six have given a buy...
Foghorn Therapeutics Inc. (NASDAQ:FHTX) Receives Average Rating of “Buy” from Brokerages
Shares of Foghorn Therapeutics Inc. (NASDAQ: FHTX - Get Free Report) have received a consensus rating of "Buy" from the nine analysts that are presently covering the company, MarketBeat Ratings reports. One investment analyst has rated the stock with a sell recommendation, six have given a buy...
02/03 07:00 EST - globenewswire.com
Foghorn Therapeutics to Participate in the Guggenheim Emerging Outlook: Biotech Summit
WATERTOWN, Mass., Feb. 03, 2026 (GLOBE NEWSWIRE) -- Foghorn® Therapeutics Inc. (Nasdaq: FHTX), a clinical-stage biotechnology company pioneering a new class of medicines that treat serious diseases by correcting abnormal gene expression, today announced that management will participate in the...
Foghorn Therapeutics to Participate in the Guggenheim Emerging Outlook: Biotech Summit
WATERTOWN, Mass., Feb. 03, 2026 (GLOBE NEWSWIRE) -- Foghorn® Therapeutics Inc. (Nasdaq: FHTX), a clinical-stage biotechnology company pioneering a new class of medicines that treat serious diseases by correcting abnormal gene expression, today announced that management will participate in the...
01/14 10:52 EST - prnewswire.com
Precision Killers: Why Big Pharma is Betting Billions to Beat a $170B Patent Cliff
/PRNewswire/ -- Equity-Insider.com News Commentary - The precision oncology market is hitting a massive growth spurt, projected to rocket from $110 billion
Precision Killers: Why Big Pharma is Betting Billions to Beat a $170B Patent Cliff
/PRNewswire/ -- Equity-Insider.com News Commentary - The precision oncology market is hitting a massive growth spurt, projected to rocket from $110 billion
01/13 16:05 EST - globenewswire.com
Foghorn Therapeutics Announces Closing of $50 Million Registered Direct Financing at a 30% Premium
WATERTOWN, Mass., Jan. 13, 2026 (GLOBE NEWSWIRE) -- Foghorn® Therapeutics Inc. (Nasdaq: FHTX), a clinical-stage biotechnology company pioneering a new class of medicines that treat serious diseases by correcting abnormal gene expression, today announced the closing of its $50 million registered...
Foghorn Therapeutics Announces Closing of $50 Million Registered Direct Financing at a 30% Premium
WATERTOWN, Mass., Jan. 13, 2026 (GLOBE NEWSWIRE) -- Foghorn® Therapeutics Inc. (Nasdaq: FHTX), a clinical-stage biotechnology company pioneering a new class of medicines that treat serious diseases by correcting abnormal gene expression, today announced the closing of its $50 million registered...
01/09 22:20 EST - globenewswire.com
Foghorn Therapeutics Highlights January Equity Financing, Program Progress and Strategic Objectives for 2026
Recently raised $50 million with BVF Partners, Deerfield Management, founding investor Flagship Pioneering and a leading biotech mutual fund in a transaction that will close January 13 th , 2026
Foghorn Therapeutics Highlights January Equity Financing, Program Progress and Strategic Objectives for 2026
Recently raised $50 million with BVF Partners, Deerfield Management, founding investor Flagship Pioneering and a leading biotech mutual fund in a transaction that will close January 13 th , 2026
12/18 11:40 EST - zacks.com
3 Cancer Stocks to Buy Amid Rapid Advances in Cancer Treatment
J&J, ImmunityBio and Foghorn Therapeutics stand out as oncology players amid rapid innovation in cancer care with advancing pipelines, approvals and partnerships.
3 Cancer Stocks to Buy Amid Rapid Advances in Cancer Treatment
J&J, ImmunityBio and Foghorn Therapeutics stand out as oncology players amid rapid innovation in cancer care with advancing pipelines, approvals and partnerships.
12/16 03:54 EST - defenseworld.net
Estrella Immunopharma (NASDAQ:ESLA) & Foghorn Therapeutics (NASDAQ:FHTX) Head-To-Head Contrast
Foghorn Therapeutics (NASDAQ: FHTX - Get Free Report) and Estrella Immunopharma (NASDAQ: ESLA - Get Free Report) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their earnings, risk, valuation, profitability,...
Estrella Immunopharma (NASDAQ:ESLA) & Foghorn Therapeutics (NASDAQ:FHTX) Head-To-Head Contrast
Foghorn Therapeutics (NASDAQ: FHTX - Get Free Report) and Estrella Immunopharma (NASDAQ: ESLA - Get Free Report) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their earnings, risk, valuation, profitability,...
12/01 01:27 EST - defenseworld.net
Foghorn Therapeutics Inc. (NASDAQ:FHTX) Receives Average Recommendation of “Buy” from Analysts
Shares of Foghorn Therapeutics Inc. (NASDAQ: FHTX - Get Free Report) have received a consensus recommendation of "Buy" from the eight brokerages that are presently covering the company, MarketBeat Ratings reports. One research analyst has rated the stock with a sell rating, five have given a buy...
Foghorn Therapeutics Inc. (NASDAQ:FHTX) Receives Average Recommendation of “Buy” from Analysts
Shares of Foghorn Therapeutics Inc. (NASDAQ: FHTX - Get Free Report) have received a consensus recommendation of "Buy" from the eight brokerages that are presently covering the company, MarketBeat Ratings reports. One research analyst has rated the stock with a sell rating, five have given a buy...
11/25 07:00 EST - globenewswire.com
Foghorn Therapeutics to Participate in the 8th Annual Evercore Healthcare Conference
CAMBRIDGE, Mass., Nov. 25, 2025 (GLOBE NEWSWIRE) -- Foghorn® Therapeutics Inc. (Nasdaq: FHTX), a clinical-stage biotechnology company pioneering a new class of medicines that treat serious diseases by correcting abnormal gene expression, today announced that management will participate in the 8th...
Foghorn Therapeutics to Participate in the 8th Annual Evercore Healthcare Conference
CAMBRIDGE, Mass., Nov. 25, 2025 (GLOBE NEWSWIRE) -- Foghorn® Therapeutics Inc. (Nasdaq: FHTX), a clinical-stage biotechnology company pioneering a new class of medicines that treat serious diseases by correcting abnormal gene expression, today announced that management will participate in the 8th...
11/19 10:57 EST - zacks.com
Does Foghorn Therapeutics (FHTX) Have the Potential to Rally 133.27% as Wall Street Analysts Expect?
The mean of analysts' price targets for Foghorn Therapeutics (FHTX) points to a 133.3% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Does Foghorn Therapeutics (FHTX) Have the Potential to Rally 133.27% as Wall Street Analysts Expect?
The mean of analysts' price targets for Foghorn Therapeutics (FHTX) points to a 133.3% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
11/05 09:16 EST - zacks.com
Foghorn Therapeutics Inc. (FHTX) Reports Q3 Loss, Beats Revenue Estimates
Foghorn Therapeutics Inc. (FHTX) came out with a quarterly loss of $0.25 per share versus the Zacks Consensus Estimate of a loss of $0.31. This compares to a loss of $0.31 per share a year ago.
Foghorn Therapeutics Inc. (FHTX) Reports Q3 Loss, Beats Revenue Estimates
Foghorn Therapeutics Inc. (FHTX) came out with a quarterly loss of $0.25 per share versus the Zacks Consensus Estimate of a loss of $0.31. This compares to a loss of $0.31 per share a year ago.
11/05 07:00 EST - globenewswire.com
Foghorn Therapeutics Provides Third Quarter 2025 Financial and Corporate Update
Ongoing FHD-909 (LY4050784) Phase 1 dose escalation trial in SMARCA4 (BRG1)-mutated cancer remains on track with non-small cell lung cancer (NSCLC) as the primary target population Selective CBP degrader entered non-GLP toxicology studies in Q4 2025 with potential in EP300-mutant cancers and ER+...
Foghorn Therapeutics Provides Third Quarter 2025 Financial and Corporate Update
Ongoing FHD-909 (LY4050784) Phase 1 dose escalation trial in SMARCA4 (BRG1)-mutated cancer remains on track with non-small cell lung cancer (NSCLC) as the primary target population Selective CBP degrader entered non-GLP toxicology studies in Q4 2025 with potential in EP300-mutant cancers and ER+...
Market News
×
Loading news…